X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (5) 5
index medicus (4) 4
tumors (4) 4
anti-pd-1 (3) 3
cancer (3) 3
ligands (3) 3
metastasis (3) 3
patients (3) 3
pd-l1 protein (3) 3
pembrolizumab (3) 3
safety (3) 3
solid tumors (3) 3
toxicity (3) 3
aged (2) 2
antibodies (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
antitumor activity (2) 2
apoptosis (2) 2
breast cancer (2) 2
cancer therapies (2) 2
care and treatment (2) 2
chemotherapy (2) 2
efficacy (2) 2
expression (2) 2
fatigue (2) 2
female (2) 2
hematology, oncology and palliative medicine (2) 2
humans (2) 2
immunohistochemistry (2) 2
immunotherapy (2) 2
male (2) 2
medical prognosis (2) 2
middle aged (2) 2
nausea (2) 2
pd-1 protein (2) 2
response rates (2) 2
viral antibodies (2) 2
1st-line therapy (1) 1
adenoid cystic carcinoma (1) 1
adult (1) 1
aged, 80 and over (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
anticancer properties (1) 1
antineoplastic agents - adverse effects (1) 1
anti–pd-1 (1) 1
arthralgia (1) 1
arthralgia - chemically induced (1) 1
b7-h1 antigen - analysis (1) 1
b7-h1 pd-l1 (1) 1
bladder (1) 1
breast (1) 1
cell death (1) 1
cell lung-cancer (1) 1
cell-carcinoma (1) 1
cisplatin (1) 1
clinical activity (1) 1
colitis (1) 1
ctla-4 blockade (1) 1
diagnosis (1) 1
diarrhea (1) 1
epidermal growth factor (1) 1
erbb-2 protein (1) 1
erythema (1) 1
erythema multiforme (1) 1
estrogen receptors (1) 1
estrogens (1) 1
fatigue - chemically induced (1) 1
follow-up studies (1) 1
gemcitabine (1) 1
head (1) 1
head & neck cancer (1) 1
head and neck (1) 1
hepatitis (1) 1
hypothyroidism (1) 1
immune system (1) 1
immune-system (1) 1
ipilimumab (1) 1
iridocyclitis (1) 1
laboratories (1) 1
letrozole (1) 1
lung cancer (1) 1
medical services (1) 1
melanoma (1) 1
mesothelioma (1) 1
mesothelioma - chemistry (1) 1
mesothelioma - drug therapy (1) 1
monoclonal antibodies (1) 1
monotherapy (1) 1
mpdl3280a (1) 1
multicenter (1) 1
nausea - chemically induced (1) 1
neoplasm metastasis (1) 1
neoplasm recurrence, local - drug therapy (1) 1
neoplasm recurrence, local - pathology (1) 1
neoplasm staging (1) 1
neoplasms. tumors. oncology. including cancer and carcinogens (1) 1
non-randomized controlled trials as topic (1) 1
open-label (1) 1
original (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, ISSN 0277-3732, 11/2018, Volume 41, Issue 11, pp. 1083 - 1088
Objectives: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for... 
pembrolizumab | HEAD | PHASE-II TRIAL | salivary gland cancer | THERAPY | ONCOLOGY | immunotherapy | PD-L2 EXPRESSION | ADENOID CYSTIC CARCINOMA | anti-PD-1 | Head and Neck | Original
Journal Article
BMC CANCER, ISSN 1471-2407, 03/2019, Volume 19, Issue 1, pp. 196 - 9
BackgroundTreatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated... 
DIAGNOSIS | Pembrolizumab | Thyroid cancer | Anti-PD-1 | IMMUNE-SYSTEM | ONCOLOGY | Immunotherapy | PD-L1 | PD-1 | Anti–PD-1
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.